Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib-IIA Study of Combined Check Point Inhibition After Autologous Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence

NCT02681302 is registered in ClinicalTrials.gov with Hackensack Meridian Health as lead sponsor.

NCT NCT02681302
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02681302 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib-IIA Study of Combined Check Point Inhibition After Autologous Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence
Lead sponsor
Hackensack Meridian Health
Phase
Phase 1/2
Overall status
Terminated
Start date
June 7, 2016
Completion date
May 10, 2024
Enrollment
46 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, multiple myeloma